CAS No.
[220347-05-7 (Unlabeled)]
Therapeutic Uses
Anti-Thrombotics
Storage Condition
Store at refrigerator (2-8°C) for long term storage
Synonyms
(1S,2R,3S,4R)-4-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-((propyl-d7)thio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)cyclopentane-1,2,3-triol
Application Notes
Useful research chemical for a range of applications
Purity by HPLC
Not less than 95 %
Hazard Compound
No -Refer MSDS for accurate information
Ticagrelor Metabolite-M8,d7 is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Ticagrelor Metabolite-M8,d7 usage and description
Ticagrelor metabolite-M8 D7 is an important chemical entity that plays a vital role in the treatment of cardiovascular diseases. Ticagrelor is an oral antiplatelet agent that is widely used for the prevention of thromboembolic events in patients with acute coronary syndrome. Ticagrelor is metabolized in the liver, and one of its major metabolites is M8 D7. Ticagrelor metabolite-M8 D7 is formed through the oxidation of ticagrelor by cytochrome P450 enzymes.
Ticagrelor metabolite-M8 D7 has been extensively studied for its pharmacological properties and chemical characteristics. It has been found to be a potent inhibitor of platelet aggregation, which is essential in the prevention of thromboembolic events. Ticagrelor metabolite-M8 D7 is also known to have a long half-life, which contributes to its efficacy in the prevention of cardiovascular events.
Chemically, Ticagrelor metabolite-M8 D7 is a structurally complex molecule that contains multiple functional groups, including a carboxylic acid, a lactam, and an amide. It has a molecular weight of 522.6 g/mol and a molecular formula of C26H23ClN6O4. Ticagrelor metabolite-M8 D7 is typically administered orally in the form of tablets or capsules, and its dosage is determined based on the patient's medical condition and response to treatment.
In conclusion, Ticagrelor metabolite-M8 D7 is an important chemical entity that is widely used for the prevention of thromboembolic events in patients with acute coronary syndrome. It is a potent inhibitor of platelet aggregation and has a long half-life, which contributes to its efficacy in the prevention of cardiovascular events. Its chemical properties and pharmacological characteristics make it an important drug in the treatment of cardiovascular diseases.
